PARP1 and Hepatic fibrosis: –Reduction in total cholesterol, LDL, IDL, and TG (PAP inhibition) levels in plasma.–Reduction in fasting plasma glucose levels.–Increased HDL levels.–Reduction in inflammation and liver fibrosis through PARP inhibition.–Increased PKB phosphorylation.